Oral IL-23 Blocker for Psoriasis Promising: Phase 2b Study Oral IL-23 Blocker for Psoriasis Promising: Phase 2b Study

An investigational IL-23R antagonist demonstrated significantly greater efficacy across all doses in patients with moderate to severe psoriasis compared with placebo at week 16 in the FRONTIER 1 study.Medscape Medical News

Source: Medscape Dermatology Headlines - July 7, 2023 Category: Dermatology Tags: Dermatology News Source Type: news